ACR: Most Hospitalizations for Gout Are Preventable

This article originally appeared here.
Share this content:
ACR: Most Hospitalizations for Gout Are Preventable
ACR: Most Hospitalizations for Gout Are Preventable

(HealthDay News) -- Most hospitalizations for a primary diagnosis of gout are preventable, according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 14 to 19 in Boston.

Thomas M. Harrington, M.D., and Thomas P. Olenginski, M.D., from the Geisinger Medical Center in Danville, Penn., examined hospitalizations related to gout and assessed whether these were preventable. Data were collected in a retrospective cohort of 79 adult patients with a primary discharge diagnosis of gout.

The researchers found that 56 of the 79 patients had adjudicated primary diagnosis of gout. Eighty-nine percent of these admissions (50 patients) met the definition of being preventable. Thirty-three of the 50 preventable admissions underwent arthrocentesis; 24 of these were performed in the emergency department. Seventy percent of the patients had a prior history of gout, and 42 percent had three or more risk factors for gout. The total additive length of stay was 171 days for preventable admissions (mean, 3.42 days). The average cost per admission was $4,160, with total hospital-related costs of $208,000.

"Too many of these admissions were indeed preventable, but most of the time, the rheumatology department was called in after the patient had already been admitted to the hospital," Olenginski said in a statement. "To effectively deal with this problem in a busy emergency department, a collaborative approach between the emergency department, rheumatology, orthopedics, and internal medicine is necessary."

Abstract
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »